<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130489</url>
  </required_header>
  <id_info>
    <org_study_id>20/SC/0301</org_study_id>
    <nct_id>NCT05130489</nct_id>
  </id_info>
  <brief_title>CAR T Cell Therapy Related Cardiovascular Outcomes</brief_title>
  <acronym>CARTCO</acronym>
  <official_title>Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a cohort study of all patients receiving Cluster of Differentiation 19&#xD;
      (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological&#xD;
      malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers,&#xD;
      ECG, transthoracic echocardiogram and cardiac magnetic resonance imaging performed at&#xD;
      baseline prior to CAR T cell therapy, 7 days post CAR T cell infusion, and 3 months post CAR&#xD;
      T cell infusion. Abnormalities in these cardiac investigations will be used to demonstrate&#xD;
      cardiac injury and identify which patients are most at risk of developing cardiac injury&#xD;
      related to CAR T cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-specific chimeric antigen receptor (CAR) T cells are a novel therapy for relapsing or&#xD;
      refractory blood cancers, which have delivered a significant improvement in the rates of&#xD;
      complete and partial remission. However, they are associated with toxicities, with some of&#xD;
      early evidence suggestive of cardiovascular involvement. Despite this, the full extent of&#xD;
      cardiovascular toxicity is poorly understood.&#xD;
&#xD;
      This research study seeks to understand the cardiac safety of CAR T cells in patients who&#xD;
      receive this therapy as part of standard care for relapsed/refractory B-cell blood cancer.&#xD;
      They will be assessed for cardiovascular risk factors via history, blood biomarkers, and&#xD;
      cardiac imaging tests. These parameters will be repeated at 7 days following administration&#xD;
      of the CAR T cells or if there are signs of cardiovascular deterioration, and again at 3&#xD;
      months follow up.&#xD;
&#xD;
      The aim is to predict the cohort most at risk of cardiovascular toxicity, and demonstrate&#xD;
      evidence of cardiac injury on the cardiac imaging scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detected abnormalities - Composite</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome is a composite of detected abnormalities on biomarkers, transthoracic echocardiogram (TTE), or Cardiac magnetic resonance (CMR) following CAR T cell infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detected abnormalities - Individual</measure>
    <time_frame>3 months</time_frame>
    <description>The secondary outcome measures includes a composite of detected abnormalities of factors on cardiac biomarkers (troponin and N-terminal pro B-type natriuretic peptide) , electrocardiogram (ECG) changes and acute heart failure.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Lymphoma Refractory</condition>
  <condition>B-cell Lymphoma Recurrent</condition>
  <condition>Primary Mediastinal Large B-cell Lymphoma (PMBCL)</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Cardiotoxicity</condition>
  <condition>Cardiovascular Complication</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum will be separated from whole blood and retained for follow-on analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving CD19-specific CAR T cell therapy for the management of relapsing or&#xD;
        refractory haematological malignancy at the MacMillan Cancer Centre within the University&#xD;
        College London Hospital will be considered for participation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with capacity, (aged 16 and older)&#xD;
&#xD;
          -  Undergoing CAR T cells for treatment for relapsing or refractory haematological&#xD;
             malignancies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 16 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Chen, BMED, FRACP</last_name>
    <phone>(+44) 20 3447 9888</phone>
    <email>daniel.chen2@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Giesz, BSc</last_name>
    <phone>(+44) 20 3447 9888</phone>
    <email>s.giesz@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Chen, BMED, FRACP</last_name>
      <phone>(+44) 20 3447 9888</phone>
      <email>daniel.chen2@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Derek Yellon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cardio-oncology</keyword>
  <keyword>CAR T cell therapy</keyword>
  <keyword>Cardiotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

